Bristol Myers Squibb offers an attractive 4% dividend yield, well above the S&P 500's 1.1% and pharma sector average of 1.7%. Trading 25% below late 2022 highs with a sustainable 70% payout ratio and strong dividend growth history, BMY could serve as a foundation for long-term wealth building through dividend reinvestment, despite current market focus on GLP-1 drugs and upcoming patent expirations.

Fight Colorectal Cancer launches its fifth annual United in Blue installation on the National Mall from March 1-14, 2026, featuring over 27,000 blue flags representing people under 50 projected to be diagnosed with colorectal cancer in 2030. The installation comes as new American Cancer Society research confirms colorectal cancer has become the deadliest cancer for Americans under 50, with mortality increasing in 2025.

Ahead of the March 6, 2026 FDA decision on Bristol Myers Squibb's Sotyktu (deucravacitinib) for psoriatic arthritis, a survey of 104 U.S. rheumatologists shows strong pre-launch awareness with one-third viewing it as a substantial advance. However, BMS ranks lowest among major pharmaceutical partners in rheumatology and is expected to capture roughly one-fifth of PsA patients through brand-to-brand share shifts rather than market expansion. The launch represents a critical opportunity for BMS to strengthen its standing in the specialty.

Bristol Myers Squibb announced positive interim Phase 3 trial results for izalontamab brengitecan (Iza-bren), a breast cancer drug developed with SystImmune, showing statistically significant improvements in progression-free and overall survival for triple-negative breast cancer patients. Despite the positive clinical data, BMY shares declined 0.56% on Thursday, trading below key moving averages with mixed technical indicators.

The global Advanced Drug Delivery Systems market is projected to grow from $299.6 billion in 2025 to $487.4 billion by 2030 at a CAGR of 10.2%. Growth is driven by increasing chronic disease prevalence, nanotechnology advances, and R&D investments. Oncology leads adoption, with North America dominating market share while Asia-Pacific shows the fastest growth. Key innovations include strategic partnerships in antibody-drug conjugates and AI-powered drug development optimization.

Kyverna Therapeutics announced the appointments of Sravan K. Emany and Andrew Miller to its Board of Directors as the company advances toward commercialization of its cell therapies for autoimmune diseases. Emany, currently CFO of Beam Therapeutics, brings capital markets and rare disease expertise, while Miller, a Time Magazine honoree and former Karuna Therapeutics leader, adds clinical development and product approval experience. Dan Spiegelman has stepped down from the Board.

Bristol-Myers Squibb announced positive topline results from a Phase 2 study of Reblozyl for treating Alpha-Thalassemia, an inherited blood disorder. The study met its primary endpoints, showing significant increases in hemoglobin levels and reduced transfusion burden. The company plans to present results at a medical congress and discuss findings with Chinese regulators. BMY stock was up 0.78% at $61.14 at publication.

Starton Therapeutics announced the dosing of the first patient in its Phase 2a clinical trial for STAR-LLD, a continuous subcutaneous delivery formulation of lenalidomide designed to treat relapsed/refractory multiple myeloma. The study will enroll 24 patients with an option to expand to 69 patients, comparing three doses of STAR-LLD against oral Revlimid. The trial has expanded from two to six investigational sites across the United States, with enrollment expected to complete in the first half of 2027.

A comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations and bispecific antibodies.

A comprehensive market report on checkpoint inhibitors covering 50+ companies and 60+ drugs in oncology. The report highlights key players like Bristol Myers Squibb, Genentech, and emerging companies such as OncoC4 and Transcode Therapeutics, with analysis of marketed therapies, pipeline products, and recent industry collaborations and acquisitions in the immuno-oncology space.

The global Hepatitis B treatment market is valued at USD 4.52 billion in 2025 and is projected to reach USD 7.74 billion by 2033, growing at a CAGR of 6.97%. Growth is driven by expanded screening programs, increased antiviral therapy adoption, and novel treatment innovations. The U.S. market is expected to grow from USD 1.00 billion to USD 1.54 billion by 2033.

The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.